PanTheryx® Introduces Relesium™—Groundbreaking, All-Natural Ingredient Addresses Gastrointestinal Side Effects of Popular Weight-Loss Drugs
Peer-Reviewed Data and Promising Study Results
A new publication in Nutrients, a leading peer-reviewed journal on human nutrition, has highlighted the potential of Relesium for gut health and GLP-1 users. Professor Raymond Playford, a gastroenterologist and scientific advisor for PanTheryx, and Professor of Molecular Medicine at the University of West London, authored the article that consolidates the growing body of research on chicken egg powder and bovine colostrum. According to Dr. Playford’s analysis, both ingredients offer significant gut-stabilizing benefits, particularly when used in combination due to their synergistic effects.
Dr. Playford explains that “the combination of egg and bovine colostrum not only supports gut stability but also delivers high-quality protein and essential micronutrients—vitamins, minerals, and antioxidants—particularly important for GLP-1 users who may experience reduced appetite and energy depletion.”
Building on these findings, PanTheryx commissioned an observational pilot study led by its Scientific Advistory Board Members, Harry Oken, M.D., and Michael Roizen, M.D., to explore Relesium’s effectiveness among GLP-1 medication patients. Eighteen participants using GLP-1 medications were enrolled in the study, ten of whom experienced gastrointestinal symptoms and were administered Relesium. Initial results are promising, showing that all ten reported notable improvement and reduced gut-related symptoms after adding Relesium to their regimen. Encouraged by these findings, a placebo-controlled trial is planned to further validate Relesium’s efficacy.
A Market-Ready Solution for GLP-1 Users
As the parent company of Relesium, PanTheryx is committed to making this gut-health solution widely accessible. “With Relesium, we’re entering a largely untapped market where there’s a significant need for an all-natural, fast-acting solution to alleviate the GI discomfort experienced by millions of GLP-1 users worldwide, while helping restore the gut microbiome,” said Tom Feeley, CEO of PanTheryx. “Health and wellness companies now have an opportunity to offer their customers a patented, science-backed product that addresses these challenges without compromising the effectiveness of their GLP-1 therapy.”
Relesium is launching in powder format, which can be used as a standalone supplement or within other product formulations starting January 2025. Additional formats and formulations are under development for future applications.
To read the full study, visit: https://www.mdpi.com/2072-6643/16/21/3684
